drinking on retatrutide and Alcohol Retatrutide and Alcohol: Can You

Improving axial resolution in confocal microscopy with new high refractive index mounting media

Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

Author Bio Julia Malkowski ND, DC, BSc Dr

Common ICD-10-CM Codes Type 2 Diabetes E11.9 Type 2 diabetes mellitus without complications E11.65 Type 2 diabetes mellitus with hyperglycemia E11.8 Type 2 diabetes mellitus with unspecified complications Obesity / Weight Management E66.9 Obesity, unspecified E66.01 Morbid (severe) obesity due to excess calories Z68.30Z68.45 BMI codes (required by many payers) Prediabetes (often not covered for GLP-1) R73.03 Prediabetes Key Coding Tip Most payers cover GLP-1 medications only for FDA-approved indications

Dehydration worsens constipation

Tirzepatide (Mounjaro) Mounjaro arrived in Mexican pharmacies and has become increasingly available, particularly in major cities and border towns